Is Moderna’s Huge IPO in 2018 Worth the Hype?
It was a big year for biotech venture capital and initial public offerings (IPO), but no IPO was bigger than Moderna’s (NASDAQ: MRNA) public debut. The clinical-stage biotech is researching programs that use our bodies to create therapeutics proteins that could reshape treatment, but its $7.5 billion made Moderna the biggest biotech unicorn to list on a major market exchange this year. Is Moderna worth the hype?
In this clip from The Motley Fool’s Industry Focus: Healthcare, analyst Shannon Jones and Todd Campbell discuss Moderna’s business model and its pace-setting IPO.
------------------------------------------------------------------------
Subscribe to The Motley Fool's YouTube Channel:
/ themotleyfool
Or, follow our Google+ page:
https://plus.google.com/+MotleyFool/p...
Inside The Motley Fool: Check out our Culture Blog!
http://culture.fool.com
Join our Facebook community:
/ themotleyfool
Follow The Motley Fool on Twitter:
/ themotleyfool